GSK) -- on Feb. 26 because more patients than expected had died while taking it. As The Boston Business Journal points out, the trial's failure may put in jeopardy Synta's $1 billion deal with Glaxo, the bulk of which hinges on the elesclomol study continuing. Synta discontinued the SYMETRY trial studying elesclomol in patients with stage 4 metastatic melanoma after more patients died in the group taking it in combination with another drug, paclitaxel, than in a group taking paclitaxel alone. Synta also suspended trials of the drug in separate indications pending further analysis of the SYMETRY data. "Our first concern is for the safety of patients, and therefore we acted promptly to halt the SYMMETRY trial once it was evident that there were serious safety concerns," said Eric Jacobson, M.D., Chief Medical Officer, in a press release dated Feb. 26.
On Wednesday, Synta announced it had postponed its year-end earnings report and conference call to hash out numbers related to the elesclomol trials' cessation.